Owens & Minor (OMI)
(Delayed Data from NYSE)
$14.58 USD
-0.20 (-1.35%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $14.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.58 USD
-0.20 (-1.35%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $14.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Zacks News
Here's Why You Should Hold on to Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.
Has Owens & Minor (OMI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Owens & Minor (OMI) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Illumina (ILMN) Hurt by Rising Costs, Tough Competition
by Zacks Equity Research
Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.
NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up
by Zacks Equity Research
NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.
Here's Why You Should Hold on to Cardiovascular Systems (CSII)
by Zacks Equity Research
Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.
IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists
by Zacks Equity Research
IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.
Here's Why You Should Retain Thermo Fisher (TMO) For Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space
by Zacks Equity Research
Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.
Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth
by Zacks Equity Research
In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.
STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.
Here's Why You Should Retain Charles River (CRL) Stock For Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.
Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes
by Zacks Equity Research
Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.
Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects
by Zacks Equity Research
Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer
by Zacks Equity Research
Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.
Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.
Medtronic (MDT) Reports Positive Findings Backing RDN System
by Zacks Equity Research
Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.
Here's Why Owens & Minor (OMI) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Owens & Minor (OMI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.
Is Owens & Minor (OMI) a Great Stock for Value Investors?
by Zacks Equity Research
Is Owens & Minor (OMI) a great pick from the value investor's perspective right now? Read on to know more.
The Zacks Analyst Blog Highlights Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co.
by Zacks Equity Research
Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co. have been included in this Analyst Blog.
3 Stocks to Focus on With MedTech M&A Scaling New Heights
by Riya Anand
MedTech stocks like Owens & Minor (OMI), Thermo Fisher (TMO) and Medtronic (MDT) are prudent investment choices given their long-term growth potential with recent M&A deals.
Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales
by Zacks Equity Research
Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.